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S2 
 
General 
 
All chemicals were purchased from commercial sources and used without further 
purification unless otherwise noted. THF, CH2Cl2, and DMF were purified via Innovative 
Technology's Pure-Solve System. All reactions were performed under an Argon 
atmosphere. All stirring was performed with an internal magnetic stirrer. Reactions were 
monitored by TLC using 0.25 mm coated commercial silica gel plates (EMD, Silica Gel 
60F254). TLC spots were visualized by UV light at 254 nm, or developed with ceric 
ammonium molybdate or anisaldehyde or copper sulfate or ninhydrin solutions by heating 
on a hot plate. Reactions were also monitored by using SHIMADZU LCMS-2020 with 
solvents: A: 0.1% formic acid in water, B: acetonitrile. Flash chromatography was 
performed with SiliCycle silica gel (Purasil 60 Å, 230-400 Mesh). Proton magnetic 
resonance (1H-NMR) spectral data were recorded on 400, and 500 MHz instruments. 
Carbon magnetic resonance (13C-NMR) spectral data were recorded on 100 and 125 MHz 
instruments. For all NMR spectra, chemical shifts (δH, δC) were quoted in parts per million 
(ppm), and J values were quoted in Hz. 1H and 13C NMR spectra were calibrated with 
residual undeuterated solvent (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm; CD3CN: δH = 1.94 
ppm, δC = 1.32ppm; CD3OD: δH =3.31 ppm, δC =49.00 ppm; DMSO-d6: δH = 2.50 ppm, 
δC = 39.52 ppm; D2O: δH = 4.79 ppm) as an internal reference. The following 
abbreviations were used to designate the multiplicities: s = singlet, d = doublet, dd = double 
doublets, t = triplet, q = quartet, quin = quintet, hept = heptet, m = multiplet, br = broad. 
Infrared (IR) spectra were recorded on a Perkin-Elmer FT1600 spectrometer. HPLC 
analyses were performed with a Shimadzu LC-20AD HPLC system. HR-MS data were 
obtained from a Waters Synapt G2-Si (ion mobility mass spectrometer with 
nanoelectrospray ionization).  
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2-(Phenylsulfonyl)ethyl ((R)-2-(((2S,3R,4R,5S,6R)-3-acetamido-5-acetoxy-6-
(acetoxymethyl)-2-(benzyloxy)tetrahydro-2H-pyran-4-yl)oxy)propanoyl)-L-
alaninate (4). The title compound was synthesized according to the reported procedure [1-
3]: 1H NMR (400 MHz, Chloroform-d) δ 7.92 (dd, J = 8.4, 1.2 Hz, 2H), 7.68 (tt, J = 7.4, 
1.3 Hz, 1H), 7.61 – 7.56 (m, 2H), 7.41 – 7.34 (m, 3H), 7.34 – 7.30 (m, 2H), 6.86 (d, J = 
6.9 Hz, 1H), 5.87 (d, J = 9.5 Hz, 1H), 5.06 (dd, J = 10.3, 9.2 Hz, 1H), 4.88 (d, J = 3.6 Hz, 
1H), 4.69 (d, J = 11.7 Hz, 1H), 4.49 (d, J = 11.8 Hz, 1H), 4.43 (hex, J = 6.0 Hz, 2H), 4.36 
(ddd, J = 10.3, 9.5, 3.7 Hz, 1H), 4.20 (dd, J = 12.3, 4.5 Hz, 1H), 4.13 (t, J = 7.1 Hz, 1H), 
4.03 (dd, J = 12.3, 2.4 Hz, 1H), 3.95 (q, J = 7.0 Hz, 1H), 3.91 (ddd, J = 10.2, 4.6, 2.4 Hz, 
1H), 3.64 (dd, J = 10.4, 9.2 Hz, 1H), 3.44 (qt, J = 6.3, 6.2 Hz, 2H), 2.11 (s, 3H), 2.07 (s, 
3H), 1.88 (s, 3H), 1.30 (d, J = 6.8 Hz, 3H), 1.29 (d, J = 7.3 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 172.02, 171.60, 170.77, 170.22, 169.32, 139.08, 136.48, 134.07, 129.44 (2C), 
128.74 (2C), 128.50, 128.33 (2C), 128.08 (2C), 97.02, 78.67, 78.45, 70.20, 69.30, 68.49, 
62.06, 58.00, 54.87, 52.89, 47.95, 23.33, 20.85, 20.78, 18.56, 16.85; HRMS (ESI+) m/z 
calcd for C33H42N2NaO13S [M + Na] 729.2305, found: 729.2320. 
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2-(Phenylsulfonyl)ethyl ((R)-2-(((2R,3R,4R,5S,6R)-3-acetamido-5-acetoxy-6-
(acetoxymethyl)-2-((bis(benzyloxy)phosphoryl)oxy)tetrahydro-2H-pyran-4-
yl)oxy)propanoyl)-L-alaninate (5). To a stirred solution of 4 (0.33 g, 0.46 mmol) in a 9:5:1 
mixture of MeOH, formic acid and H2O (15 mL) was added Pd-C (0.65 g). The reaction 
solution was stirred under hydrogen atmosphere (400 psi) for 17 h. The reaction mixture 
was filtrated and the residue was concentrated in vacuo. The crude product was purified by 
silica gel column chromatography (EtOAc/MeOH = 90/10) to afford the free-alcohol (0.26 
g, 91%). To a stirred solution of the anomeric-free alcohol (0.21 g, 0.34 mmol) and 5-
(ethylthio)-1H-tetrazole (0.13 g, 1.0 mmol) in CH2Cl2 (3.4 mL) was added dibenzyl N,N-
diisopropylphosphoramidite (0.29 mL, 0.86 mmol) at 0 oC. After 2 h at 0 oC, the reaction 
was quenched with aq. saturated NaHCO3 and extracted with CHCl3. The combined 
organic solution was dried over Na2SO4 and concentrated in vacuo. To a stirred solution of 
the crude mixture and NaHCO3 (58 mg, 0.69 mmol) in THF (3.4 mL), 70% aq. tert-butyl 
hydroperoxide (0.48 mL, 3.4 mmol) was added at 0 oC. After 30 min. at r.t., the reaction 
 
S4 
 
was quenched with aq. Na2S2O3 and extracted with CHCl3. The combined organic solution 
was dried over Na2SO4 and concentrated in vacuo. The crude mixture was purified by silica 
gel column chromatography (EtOAc/MeOH = 90/10) to afford 0.28 g (93% for 2 steps) of 
5: 1H NMR (400 MHz, Chloroform-d) δ 7.92 (dd, J = 8.4, 1.3 Hz, 2H), 7.68 (tt, J = 7.4, 
1.3 Hz, 1H), 7.61 – 7.56 (m, 2H), 7.39 – 7.32 (m, 10H), 6.73 (d, J = 7.0 Hz, 1H), 6.12 (d, 
J = 9.0 Hz, 1H), 5.62 (dd, J = 5.8, 3.2 Hz, 1H), 5.14 – 4.97 (m, 6H), 4.45 (td, J = 6.2, 1.3 
Hz, 2H), 4.33 (ddt, J = 10.6, 9.0, 3.1 Hz, 1H), 4.19 (t, J = 7.2 Hz, 1H), 4.10 (dd, J = 13.1, 
4.6 Hz, 1H), 3.92 (d, J = 13.8 Hz, 1H), 3.89 (d, J = 9.8 Hz, 1H), 3.50 – 3.41 (m, 3H), 2.07 
(s, 3H), 2.01 (s, 3H), 1.75 (s, 3H), 1.30 (d, J = 6.9 Hz, 3H), 1.29 (d, J = 7.2 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 171.93, 171.51, 170.63, 170.60, 169.12, 139.05, 134.11 (2C), 
129.47 (2C), 129.04 (2C), 128.80 (4C), 128.16 (2C), 128.08 (4C), 96.85, 96.78, 78.37, 
70.15, 70.03, 69.98, 68.65, 61.45, 58.07, 54.84, 52.92, 52.85, 47.92, 22.97, 20.79, 20.65, 
18.62, 17.00; 31P NMR (162 MHz, CDCl3) δ -2.39 ; HRMS (ESI+) m/z calcd for 
C40H49N2NaO16PS [M + Na] 899.2438, found: 899.2412. 
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Tetrapeptide  
 
Tetrapeptide. Tetrapeptide was synthesized according to the reported procedure [4-6]: 1H 
NMR (400 MHz, DMSO-d6) δ 9.45 (t, J = 5.8 Hz, 1H), 8.62 (s, 3H), 8.27 (d, J = 7.0 Hz, 
1H), 8.23 (d, J = 8.1 Hz, 1H), 8.21 (d, J = 7.8 Hz, 1H), 4.34 – 4.25 (m, 1H), 4.26 – 4.18 
(m, 2H), 3.99 (t, J = 6.7 Hz, 1H), 3.72 (s, 3H), 3.60 (s, 3H), 2.33 (ddt, J = 37.5, 15.2, 7.6 
Hz, 2H), 2.05 – 1.94 (m, 2H), 1.64 – 1.40 (m, 6H), 1.29 (d, J = 7.2 Hz, 3H), 1.27 – 1.20 
(m, 2H), 1.19 (d, J = 7.0 Hz, 3H); 13C NMR (101 MHz, DMSO) δ 173.87, 173.08, 172.26, 
171.81, 170.74, 157.10 (q, J = 35.9 Hz), 116.96 (q, J = 288.3 Hz), 53.72, 53.62, 52.81, 
52.45, 49.54, 48.58, 48.55, 32.49, 31.23, 28.89, 26.97, 23.51, 19.05, 17.72; HRMS (ESI+) 
m/z calcd for C21H35F3N5O8 [M + H] 542.2438, found: 542.2457. 
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Methyl N2-(((R)-2-(((2R,3R,4R,5S,6R)-3-acetamido-5-acetoxy-6-(acetoxymethyl)-2-
((bis(benzyloxy)phosphoryl)oxy)tetrahydro-2H-pyran-4-yl)oxy)propanoyl)-L-
alanyl)-N5-((S)-1-(((R)-1-(((R)-1-methoxy-1-oxopropan-2-yl)amino)-1-oxopropan-2-
yl)amino)-1-oxo-6-(2,2,2-trifluoroacetamido)hexan-2-yl)-D-glutaminate (6). To a 
stirred solution of 5 (78 mg, 0.089 mmol) in CH2Cl2 (0.45 mL) was added DBU (15 L, 
0.098 mmol). After being stirred for 1 h at r.t., the reaction was quenched with 1 M aq. HCl 
and extracted with EtOAc. The combined organic solution was dried over Na2SO4 and 
concentrated in vacuo. To a stirred solution of the crude mixture, tetrapeptide (0.10 g, 0.18 
mmol) and NaHCO3 (38 mg, 0.45 mmol) in 25:1 solution of DMF and H2O (1.0 mL), GOx 
(41 mg, 0.18 mmol) and EDCI (34 mg, 0.18 mmol) were added. After being stirred for 2 h 
at r.t., the reaction was quenched with aq. saturated NaHCO3 and extracted with EtOAc. 
The combined organic solution was dried over Na2SO4 and concentrated in vacuo. The 
crude mixture was purified by silica gel column chromatography (EtOAc/MeOH/Et3N = 
93/7/0.5 - 90/10/0.5) to afford 99 mg (90% for 2 steps) of 6. 1H NMR (400 MHz, 
Chloroform-d) δ 7.75 (t, J = 5.8 Hz, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.38 – 7.30 (m, 10H), 
7.15 (d, J = 5.8 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 6.88 (d, J = 8.7 Hz, 1H), 5.64 (dd, J = 
5.9, 3.2 Hz, 1H), 5.06 (ddd, J = 9.2, 8.4, 3.0 Hz, 6H), 4.54 – 4.30 (m, 7H), 4.24 (quin, J = 
6.9 Hz, 1H), 4.15 – 4.09 (m, 2H), 3.91 (d, J = 10.6 Hz, 2H), 3.70 (s, 3H), 3.68 (s, 3H), 3.69 
– 3.66 (m, 1H), 3.59 (t, J = 9.9 Hz, 1H), 3.31 (q, J = 6.5 Hz, 2H), 3.10 (q, J = 7.3 Hz, 1H), 
2.38 – 2.13 (m, 4H), 2.07 (s, 3H), 1.99 (s, 3H), 1.78 (s, 3H), 1.58 (tt, J = 13.5, 6.2 Hz, 2H), 
1.43 (d, J = 7.0 Hz, 3H), 1.38 (d, J = 7.4 Hz, 3H), 1.37 (d, J = 7.3 Hz, 3H), 1.29 (d, J = 6.6 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 173.32, 173.24, 172.73, 172.60, 172.18, 172.02, 
171.94, 171.05, 170.57, 169.26, 157.45 (q, J = 36.8 Hz), 129.00 (2C), 128.76 (4C), 128.63, 
128.56, 128.09 (4C), 70.02, 69.98, 68.63, 61.46, 53.82, 53.09, 53.01, 52.48, 52.29, 50.76, 
50.27, 49.12, 48.03, 45.85, 39.42, 31.40, 31.16, 29.66, 28.16, 27.58, 22.78, 22.36, 20.79, 
20.61, 18.54, 17.82, 17.64, 17.22, 8.57; 31P NMR (162 MHz, CDCl3) δ -2.72; HRMS (ESI+) 
m/z calcd for C53H74F3N7O21P [M + H] 1232.4628, found: 1232.4646. 
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Park’s nucleotide (10). To a stirred solution of 6 (7.5 mg, 6.1 mol) in MeOH (10 mL) 
was added Pd-C (15 mg). After being stirred under hydrogen atmosphere (1 atm) for 1 h at 
r.t., Et3N (0.5 mL) was added to the reaction mixture. After being stirred for 1 h at r.t., the 
catalyst was filtered through a pad of Celite. The filtrate solution of pentapeptide was 
concentrated in vacuo and the resulting product was dried in high vacuum. To a stirred 
solution of uridyl phosphate (62 mg, 0.15 mmol) in 1:1 solution of THF and DMF (2.0 
mL) was added CDI (74 mg, 0.46 mmol). After being stirred for 14 h at r.t., MeOH (0.2 
mL) was added to the reaction mixture. After being stirred for 1 h, the solution was 
concentrated in vacuo and the resulting product was dried in high vacuum. To a stirred 
solution of the crude product of pentapeptide in 4:1 solution of THF and DMF (2.0 mL) 
was added the crude product of uridyl phosphate. After being stirred for 48 h at r.t., the 
reaction mixture was filtered and concentrated in vacuo. To a stirred solution of the crude 
product in THF (1.7 mL) was added 1.7 mL of aq. LiOH (43.2 mg, 1.03 mmol). After being 
stirred for 2.5 h at r.t., the reaction mixture was filtered and concentrated in vacuo. The 
filtrate was purified by reverse phase HPLC [column: HYPERSIL GOLD™ (175 Å, 12 
m, 150 x 20 mm), solvents: 0 : 100 CH3CN : 0.05 M aq. NH4HCO3 for 5 min then 5 : 95 
CH3CN : 0.05 M aq. NH4HCO3 for 10 min then 10 : 90 CH3CN : 0.05 M aq. NH4HCO3 
for 10 min, flow rate: 4.0 mL/min, UV: 254nm] to afford 10 (4.7 mg, 68% overall, retention 
time: 18.7 min): 1H NMR (400 MHz, Deuterium Oxide) δ 7.95 (d, J = 8.1 Hz, 1H), 5.99 – 
5.94 (m, 2H), 5.46 (dd, J = 7.2, 3.2 Hz, 1H), 4.37 – 4.34 (m, 2H), 4.31 (d, J = 7.2 Hz, 1H), 
4.29 – 4.09 (m, 11H), 3.94 (ddd, J = 10.1, 2.3, 2.1 Hz, 1H), 3.89 – 3.81 (m, 2H), 3.78 (dd, 
J = 10.2, 9.0 Hz, 1H), 3.63 (dd, J = 10.2, 9.0 Hz, 1H), 2.99 (t, J = 7.5 Hz, 2H), 2.30 (t, J = 
7.6 Hz, 2H), 2.16 (ddd, J = 12.8, 7.7, 4.8 Hz, 1H), 2.00 (s, 3H), 1.94 – 1.84 (m, 1H), 1.83 
– 1.75 (m, 2H), 1.68 (dd, J = 8.6, 6.1 Hz, 2H), 1.43 (d, J = 7.3 Hz, 3H), 1.39 (d, J = 6.9 Hz, 
3H), 1.36 (d, J = 6.9 Hz, 3H), 1.33 (d, J = 7.1 Hz, 3H); HRMS (ESI+) m/z calcd for 
C40H66N9O26P2 [M + H] 1150.3594, found: 1150.3581. 
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Park’s nucleotide-N-C6-dansyl (1e). To a stirred solution of 10 (6.3 mg, 5.5 mol) and 
SuO-C(O)O-(CH2)6-NHCOCF3 (5.8 mg, 0.017 mmol) in MeCN (0.5 mL) was added Et3N 
(3.9 L, 0.028 mmol). After being stirred for 12 h at r.t., the reaction was concentrated in 
vacuo. To a stirred solution of the crude product in THF (0.5 mL) was added 0.2 mL of aq. 
LiOH (2.3 mg, 0.055 mmol). After being stirred for 3 h at r.t., the reaction mixture was 
filtered and concentrated in vacuo. The crude product was purified by reverse phase HPLC 
[column: HYPERSIL GOLD™ (175 Å, 12 m, 150 x 20 mm), solvents: 0 : 100 CH3CN : 
0.05 M aq. NH4HCO3 for 5 min then 5 : 95 CH3CN : 0.05 M aq. NH4HCO3 for 10 min then 
10 : 90 CH3CN : 0.05 M aq. NH4HCO3 for 10 min, flow rate: 4.0 mL/min, UV: 254nm]. 
To a stirred solution of the product and NaHCO3 (4.6 mg, 0.055 mmol) in a 4 : 1 solution 
of THF and H2O (0.5 mL) was added 4-(dansylamino)phenyl isothiocyanate (10.5 mg, 
0.028 mmol). After being stirred for 4 h at r.t., the reaction mixture was filtered and 
concentrated in vacuo. The filtrate was purified by reverse phase HPLC [column: 
Phenomenex Luna (100 Å, 10 m, C18, 250 x 10 mm), solvents: 10 : 90 CH3CN : 0.05 M 
aq. NH4HCO3 for 5 min then 20 : 80 CH3CN : 0.05 M aq. NH4HCO3 for 10 min then 30 : 
70 CH3CN : 0.05 M aq. NH4HCO3 for 10 min, flow rate: 3.0 mL/min, UV: 350nm] to 
afford 1e (6.4 mg, 70% overall, retention time: 24.7 min): 1H NMR (400 MHz, Deuterium 
Oxide) δ 8.55 (d, J = 8.2 Hz, 1H), 8.30 (d, J = 8.2 Hz, 1H), 8.15 (d, J = 7.4 Hz, 1H), 7.87 
(d, J = 8.1 Hz, 1H), 7.32 (d, J = 7.2 Hz, 1H), 7.07 (s, 1H), 6.87 (s, 4H), 5.93 (ddd, J = 3.8, 
1.6, 0.9 Hz, 1H), 5.89 (d, J = 8.0 Hz, 1H), 5.41 (dd, J = 7.7, 3.2 Hz, 1H), 4.30 (d, J = 3.3 
Hz, 3H), 4.28 – 4.01 (m, 10H), 3.92 – 3.87 (m, 1H), 3.82 – 3.77 (m, 2H), 3.74 – 3.70 (m, 
1H), 3.61 – 3.57 (m, 1H), 3.39 – 3.32 (m, 2H), 2.98 – 2.90 (m, 2H), 2.80 (s, 6H), 2.24 – 
2.18 (m, 4H), 2.14 – 2.09 (m, 3H), 1.95 (s, 3H), 1.80 – 1.76 (m, 1H), 1.62 – 1.43 (m, 4H), 
1.37 (d, J = 7.5 Hz, 3H), 1.34 (d, J = 7.1 Hz, 3H), 1.28 (d, J = 7.0 Hz, 3H), 1.26 (d, J = 6.9 
Hz, 3H), 1.17 – 1.11 (m, 4H), 0.86 – 0.78 (m, 4H); HRMS (ESI+) m/z calcd for 
C66H96N13O30P2S2 [M + H] 1676.5303, found: 1676.5322. 
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UDP-GlcN-C6-FITC (8). The title compound was synthesized according to the reported 
procedure [7]: 1H NMR (400 MHz, Deuterium Oxide) δ 7.90 (d, J = 8.1 Hz, 1H), 7.71 – 
7.63 (m, 1H), 7.61 – 7.51 (m, 1H), 7.37 – 7.30 (m, 3H), 7.30 – 7.20 (m, 4H), 5.99 – 5.85 
(m, 2H), 5.52 (d, J = 6.3 Hz, 1H), 4.35 – 4.27 (m, 3H), 4.26 – 4.13 (m, 2H), 4.12 – 4.00 
(m, 2H), 3.92 – 3.84 (m, 1H), 3.80 (dd, J = 16.2, 3.2 Hz, 1H), 3.76 – 3.69 (m, 2H), 3.62 – 
3.56 (m, 2H), 3.54 – 3.47 (m, 1H), 3.45 – 3.37 (m, 1H), 1.70 – 1.57 (m, 4H), 1.46 – 1.33 
(m, 4H); HRMS (ESI+) m/z calcd for C44H51N5NaO23P2S [M + H] 1134.2069, found: 
1134.2084. 
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Lipid I (7). To a stirred solution of 6 (9.2 mg, 7.5 mol) in MeOH (10 mL) was added Pd-
C (18 mg). After being stirred under hydrogen atmosphere (1 atm) for 1 h at r.t., Et3N (0.5 
mL) was added to the reaction mixture. After being stirred for 1 h at r.t., the catalyst was 
filtered through a pad of Celite. The filtrate solution was concentrated in vacuo and the 
resulting product was dried in high vacuum. To a stirred solution of the crude product in 
3:1 solution of THF and DMF (0.5 mL) was added CDI (3.6 mg, 0.023 mmol). After being 
stirred for 3 h at r.t., MeOH (20 L) was added to the reaction mixture. After being stirred 
for 30 min, the solution was concentrated in vacuo and the resulting product was dried in 
high vacuum. To a stirred solution of the crude product in 3:1 solution of THF and DMF 
(0.5 mL) was added C55-P-NH4 (5.3 mg, 6.0 mol). After being stirred for 48 h at r.t., the 
reaction mixture was filtered and concentrated in vacuo. To a solution of the crude product 
in THF (0.5 mL) was added 0.05 mL of aq. LiOH (3.2 mg, 0.075 mmol). After being stirred 
for 3 h at r.t., the reaction mixture was filtered and concentrated in vacuo. The filtrate was 
purified by reverse phase HPLC [column: Phenomenex Luna (100 Å, 10 m, C18, 250 x 
10 mm), solvents: a gradient elution of 85 : 15 to 100 : 0 MeOH : 0.05 M aqueous 
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NH4HCO3 over 30 min, flow rate: 3.0 mL/min, UV: 220nm] to afford 7.5 mg (60% overall) 
of 7 (retention time: 24.3 min). 1H NMR (400 MHz, Methanol-d4) δ 5.57 – 5.51 (m, 1H), 
5.48 – 5.42 (m, 1H), 5.18 – 5.06 (m, 11H), 4.55 – 4.48 (m, 2H), 4.41 – 4.10 (m, 6H), 4.03 
– 3.96 (m, 1H), 3.88 (q, J = 10.3 Hz, 2H), 3.74 (dd, J = 12.3, 5.1 Hz, 1H), 3.53 (t, J = 9.5 
Hz, 1H), 2.99 – 2.88 (m, 2H), 2.79 (s, 1H), 2.31 (s, 3H), 2.14 – 2.03 (m, 31H), 1.99 (q, J = 
7.8, 7.1 Hz, 8H), 1.90 – 1.78 (m, 2H), 1.74 (s, 3H), 1.68 (s, 21H), 1.63 – 1.58 (m, 10H), 
1.47 (d, J = 7.2 Hz, 3H), 1.41 (t, J = 6.7 Hz, 6H), 1.36 (d, J = 7.2 Hz, 3H), 1.30 (d, J = 7.6 
Hz, 8H), 0.89 (d, J = 8.1 Hz, 2H); HRMS (EI) calcd for C86H144N7O21P2 ([M + H]
+): 
1672.9891, found: 1672.9908. 
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C55-Lipid I-N-C6-dansyl (2e-C55). To a stirred solution of 7 (4.4 mg, 2.6 mol) and SuO-
C(O)O-(CH2)6-NHCOCF3 (4.6 mg, 0.013 mmol) in MeCN (0.5 mL) was added Et3N (3.6 
L, 0.026 mmol). After being stirred for 12 h at r.t., the solution was concentrated in vacuo. 
To a stirred solution of the crude product in THF (0.5 mL) was added 0.05 mL of aq. LiOH 
(1.1 mg, 0.026 mmol). After being stirred for 1 h at r.t., the reaction mixture was filtered 
and concentrated in vacuo. The crude product was purified by reverse phase HPLC 
[column: Phenomenex Luna (100 Å, 10 m, C18, 250 x 10 mm), solvents: a gradient 
elution of 85 : 15 to 100 : 0 MeOH : 0.05 M aqueous NH4HCO3 over 30 min, flow rate: 
3.0 mL/min, UV: 220nm]. To a stirred solution of the product and NaHCO3 (2.2 mg, 0.026 
mmol) in 4 : 1 solution of THF and H2O (0.5 mL) was added 4-(dansylamino)phenyl 
isothiocyanate (5.0 mg, 0.013 mmol). After being stirred for 4 h at r.t., the reaction mixture 
was filtered and concentrated in vacuo. The filtrate was purified by reverse phase HPLC 
[column: Phenomenex Luna (100 Å, 10 m, C18, 250 x 10 mm), solvents: a gradient 
elution of 85 : 15 to 100 : 0 MeOH : 0.05 M aqueous NH4HCO3 over 30 min, flow rate: 
3.0 mL/min, UV: 350nm] to afford 2e-C55 (4.6 mg, 80% overall, retention time: 23.4 min): 
1H NMR (400 MHz, Methanol-d4) δ 7.97 (s, 1H), 7.76 – 7.71 (m, 1H), 7.58 (d, J = 8.9 Hz, 
1H), 7.32 (t, J = 7.7 Hz, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.02 (d, J = 7.5 Hz, 1H), 5.49 – 5.42 
(m, 1H), 5.39 (t, J = 5.7 Hz, 1H), 5.31 – 5.25 (m, 1H), 5.12 – 4.99 (m, 11H), 4.46 (t, J = 
6.4 Hz, 2H), 4.34 – 4.05 (m, 6H), 4.00 – 3.88 (m, 3H), 3.82 (d, J = 11.8 Hz, 1H), 3.61 (td, 
J = 14.4, 13.4, 6.5 Hz, 3H), 3.54 (s, 1H), 3.50 – 3.37 (m, 2H), 3.12 (q, J = 7.3 Hz, 2H), 
3.04 – 2.94 (m, 1H), 2.29 – 2.15 (m, 4H), 2.07 – 1.88 (m, J = 8.8, 7.9 Hz, 41H), 1.66 (s, 
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3H), 1.61 (s, 21H), 1.55 – 1.51 (m, 10H), 1.46 – 1.40 (m, 3H), 1.33 (dt, J = 18.1, 7.1 Hz, 
12H), 1.22 (d, J = 5.0 Hz, 18H). 
 
 
 
Me Me Me
HO
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Me
Me
 
 
(2Z)-Phytol was purchased as an E/Z mixture, and used after purification by silica gel 
column chromatography (hexanes/EtOAc = 95/5): 1H NMR (400 MHz, Chloroform-d) δ 
5.41 (td, J = 7.1, 1.4 Hz, 1H), 4.13 (t, J = 3.4 Hz, 2H), 2.09 – 2.01 (m, 2H), 1.74 (d, J = 1.1 
Hz, 3H), 1.56 – 1.46 (m, 1H), 1.45 – 1.21 (m, 14H), 1.16 – 1.01 (m, 4H), 0.89 – 0.82 (m, 
12H); 13C NMR (101 MHz, CDCl3) δ 140.66, 123.97, 59.16, 39.39, 37.44, 37.37, 37.30, 
36.86, 32.80, 32.70, 32.21, 27.99, 25.71, 24.80, 24.47, 23.45, 22.72, 22.63, 19.75, 19.69; 
HRMS (EI) calcd for C20H41O ([M + H]
+): 297.3157, found: 297.3172. 
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(2Z)-Phytyl phosphate. To a stirred solution of phosphoric acid (9.80 mg, 0.10 mmol), 
pyridine (40.4 L, 0.50 mmol), and (2Z)-phytol S1 (126 mg, 0.42 mmol) was added Et3N 
(27.9 L, 0.20 mmol). After being stirred for 30 min, Ac2O (18.9 L, 0.20 mmol) was 
added to the reaction mixture. After being stirred for 24 h at 80 oC, the reaction mixture 
was cooled to r.t., and the reaction was quenched with water (1 mL). After being stirred for 
1 h at 80 oC, the reaction mixture was cooled to r.t., and the aqueous solution was washed 
with ether. The aqueous solution was lyophilized, and the crude mixture was purified by 
DOWEX 50WX8 afforded (2Z)-phytyl phosphate (24.5 mg, 65%): 1H NMR (400 MHz, 
Methanol-d4) δ 5.41 (td, J = 7.0, 1.5 Hz, 1H), 4.42 (td, J = 6.7, 1.2 Hz, 2H), 3.20 (q, J = 
7.3 Hz, 2H), 2.09 (ddd, J = 8.3, 6.5, 3.4 Hz, 2H), 1.73 (d, J = 1.3 Hz, 3H), 1.54 (dp, J = 
13.1, 6.6 Hz, 1H), 1.46 – 1.01 (m, 16H), 0.95 – 0.78 (m, 12H); 13C NMR (101 MHz, 
MeOD) δ 141.20, 123.10, 123.02, 63.10, 63.05, 40.54, 38.52, 38.50, 38.39, 37.95, 33.94, 
33.22, 29.14, 26.70, 25.88, 25.51, 23.55, 23.08, 22.99, 20.18, 20.11, 9.19; 31P NMR (162 
MHz, MeOD) δ 1.08; HRMS (EI) calcd for C20H42O4P ([M + H]
+): 377.2821, found: 
377.2838. 
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C20-Lipid I. The title compound was synthesized according to the procedure described for 
Lipid I (7): 1H NMR (400 MHz, Methanol-d4) δ 5.54 (d, J = 7.3 Hz, 1H), 5.43 (q, J = 6.6 Hz, 1H), 
4.54 (t, J = 6.6 Hz, 2H), 4.41 – 4.09 (m, 6H), 4.02 – 3.95 (m, 1H), 3.92 – 3.79 (m, 2H), 3.74 (dd, J 
= 12.1, 5.1 Hz, 1H), 3.53 (t, J = 9.5 Hz, 1H), 2.98 – 2.89 (m, 2H), 2.32 (s, 3H), 2.13 – 2.05 (m, 
1H), 2.05 – 1.97 (m, 5H), 1.91 – 1.77 (m, 2H), 1.69 (s, 3H), 1.60 – 1.50 (m, 4H), 1.47 (d, J = 7.2 
Hz, 4H), 1.45 – 1.35 (m, 14H), 1.35 – 1.22 (m, 10H), 1.19 – 1.04 (m, 4H), 0.88 (t, J = 6.4 Hz, 12H); 
HRMS (EI) calcd for C51H94N7O21P2 ([M + H]+): 1202.5978, found: 1202.5995. 
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C20-Lipid I-N-C6-dansyl (2e-C20). The title compound was synthesized according to the 
procedure described for C55-Lipid I-N-C6-dansyl (2e-C55): 
1H NMR (400 MHz, Methanol-
d4) δ 8.55 (d, J = 8.2 Hz, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.19 (d, J = 7.4 Hz, 1H), 7.76 (d, J 
= 8.2 Hz, 1H), 7.57 (q, J = 7.5 Hz, 1H), 7.27 (d, J = 7.2 Hz, 1H), 6.96 (s, 4H), 5.41 – 5.21 
(m, 2H), 4.88 – 4.81 (m, 2H), 4.38 – 4.29 (m, 2H), 4.12 (tdd, J = 19.8, 11.3, 5.6 Hz, 6H), 
4.01 (dd, J = 10.9, 5.4 Hz, 1H), 3.91 (t, J = 6.5 Hz, 2H), 3.85 – 3.78 (m, 2H), 3.74 – 3.68 
(m, 1H), 3.54 (dt, J = 10.4, 7.1 Hz, 2H), 3.50 – 3.46 (m, 1H), 3.35 (d, J = 1.2 Hz, 2H), 3.27 
– 3.21 (m, 1H), 3.15 – 3.11 (m, 1H), 2.90 – 2.77 (m, 8H), 2.61 – 2.53 (m, 2H), 2.39 – 2.29 
(m, 4H), 2.26 – 2.22 (m, 2H), 2.15 (t, J = 7.6 Hz, 2H), 2.06 (d, J = 5.5 Hz, 3H), 2.02 (d, J 
= 1.2 Hz, 3H), 1.89 (d, J = 1.2 Hz, 4H), 1.61 (q, J = 7.9 Hz, 2H), 1.53 (q, J = 6.4, 5.9 Hz, 
2H), 1.41 (d, J = 1.2 Hz, 2H), 1.31 (dd, J = 9.1, 5.0 Hz, 26H), 0.90 (t, J = 6.6 Hz, 12H); 
HRMS (ESI+) m/z calcd for C77H124N11O25P2S2 [M + H] 1728.7687, found: 1728.7669. 
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Bacterial strains and growth of bacteria 
Mycobacterium smegmatis (ATCC 607), Staphylococcus aureus (BAA-1683), Bacillus 
subtilis (ATCC 6051), and E. coli (ATCC 10798) were obtained from American Type 
Culture Collection (ATCC). A single colony of Mycobacterium smegmatis was obtained 
on Difco Middlebrook 7H10 nutrient agar enriched with with albumin, dextrose, and 
catalase (ADC). Single colonies of S.aureus and E. coli were grown on tryptic soy agar for 
24 h at 37oC in a static incubator and cultured in tryptic soy broth until log phase to be an 
optical density (OD) of 0.2-0.5. The OD was monitored at 600 and 570 nm using a 96-well 
microplate reader. A single colony of C. difficile was obtained on a BHI agar plate and 
incubated at 37 oC under anaerobic conditions for 48 h (Gas: 10% hydrogen, 5% carbon 
dioxide and 85% nitrogen mixture was used. Chambers: Plas Labs™ Model 855 Anaerobic 
Chambers was used.). The other bacteria were cultured in the recommended conditions by 
ATCC. 
 
 
 
MIC assays 
Minimum inhibitory concentrations were determined by broth dilution microplate alamar 
blue assay or by OD measurement. All compounds were stored in DMSO or water (1 
mg/100 L concentration). This concentration was used as the stock solution for all MIC 
studies. Each compound from stock solution was placed in the first well of a sterile 96 well 
plate and a serial dilution was conducted with the culturing broth (total volume of 10 L). 
The bacterial suspension at log phase (190 L) was added to each well (total volume of 
200 L). M. smegmatis, S. aureus, E. coli, and the aerobic bacteria were incubated for 24 
h (48-72 h for M. smegmatis) at 37 oC. 20 L of resazurin (0.02%) was added to each well 
and incubated for 4 h for Mycobacterium spp., and 1 h for the other bacteria (National 
Committee for Clinical Laboratory Standards (NCCLS) method (pink = growth, blue = no 
visible growth)).The OD measurements were performed for all experiments prior to 
colorimetric The anaerobic bacteria were applied to a microplate reader. The MIC values 
were determined according to the colorimetric assays using resazurin. The absorbance of 
each well was also measured at 570 and 600 nm via UV-Vis. If necessary, CFU method 
was applied to confirm bactericidal activity. MIC against M. tuberculosis was performed 
at UTHSC RBL. Due to the compliance, images acquired in the BSL-3 in RBL are 
prohibited to show. The MIC data were recorded on laminated paper. 
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Figure S1. MIC assay against M. smegmatis (ATCC607). 
 
 
 
 
Preparation of membrane fraction P-60 containing MraY and MurG 
M. smegmatis cells were harvested by centrifugation (4700 rpm) at 4 oC followed by 
washing with 0.9% saline solution (thrice). The washed cell pellets were washed with 
homogenization buffer (containing 50 mM K2HPO4, 5 mM MgCl2, 5 mM 1,4-dithio-DL-
threitol, and 10% glycerol, pH = 7.2) (thrice), and approximately 5 g of pellet (wet weight) 
was collected. The washed cell pellets were suspended in homogenization buffer and 
disrupted by probe sonication on ice (5 s on and 2 s off for 1 min, then cool down for 1.5 
min, 5 cycles, cool down for 15 min, and then, 5 s on and 2 s off for 1 min, cool down for 
1.5 min, 5 cycles). The resulting suspension was centrifuged at 4,700 x g for 15 min at 4 
oC to remove unbroken cells. The lysate was centrifuged at 25,000 x g for 20 min at 4 oC. 
The supernatant was subjected to ultracentrifugation at 60,000 x g for 1 h at 4 oC. The 
supernatant was discarded, and the membrane fraction containing MurG enzyme (P-60) 
was suspended in the Tris-HCl buffer (pH = 7.5). Total protein concentrations were 
approximately 8 to 10 mg/mL. Aliquots were stored in Eppendorf tubes at -80 oC. Similarly, 
the membrane fractions containing WecA enzyme (P-60) were prepared from E. coli. 
 
 
 
MurG assay. 
MurG assay substrates, Park’s nucleotide-Nε-C6-dansyl, UDP-GlcN- N
ε-C6-FITC, were 
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chemically synthesized according to the reported procedures. 
 
 
 
Protocol A: 
Park’s nucleotide-Nε-C6-dansylthiourea (1e) (2 mM stock solution, 1.88 μL), CHAPS (20%, 
1.25 μL), -mercaptoethanol (50 mM, 5 μL), MgCl2 (0.5 M, 5 μL), KCl (2 M, 5 μL), and 
C55-phosphate dissolved in NaHCO3 (50 mM) : DMSO (1 : 4) (4 mM, 2.81 μL) were placed 
in a 1.5 mL Eppendorf tube. To a stirred reaction mixture, HyMraY (4.18 mg/mL, 1 μL) 
was added (total volume of reaction mixture: 50 μL adjust with Tris buffer (50 mM, pH = 
8.0)). The reaction mixture was incubated for 1 h at 37 oC. To a reaction mixture, inhibitor 
molecule (0 - 100 g/mL in Tris buffer), UDP-GlcNAc (10 mM stock solution, 1.88 μL), 
and P60 (1 mg/μL, 30 μL) or HyMurG (5.2 mg/mL, 5 μL) were added. The reaction mixture 
was incubated for 1 h at 37 oC, and quenched with water saturated n-butanol (150μL). Two 
phases were mixed via vortex for 2 min and centrifuged at 25,000 xg for 10 min. The upper 
n-butanol phase was assayed via reverse-phase HPLC. The n-butanol phase (30 μL) was 
injected into HPLC (solvent: a gradient elution of CH3OH/0.05 M aq. NH4HCO3 = 70 : 30 
to 100 : 0 over 30 min; UV: 350 nm; flow rate: 1.0 mL/min; column: Luna 5μm C8, 100 A, 
250 x 4.60 mm), and the area of the peak for C55-lipid II-N
ε-C6-dansyl-FITC was quantified 
to obtain the IC50 value. The IC50 values were calculated from plots of the percentage 
product inhibition versus the inhibitor concentration. All inhibition curves, Michaelis-
Menten plots and Lineveaver-Burk plots were obtained by using GraphPad Prism 7.04. 
 
Protocol B: 
Park’s nucleotide-Nε-C6-dansylthiourea (1e) (2 mM stock solution, 1.88 μL), CHAPS (20%, 
1.25 μL), -mercaptoethanol (50 mM, 5 μL), MgCl2 (0.5 M, 5 μL), KCl (2 M, 5 μL), and 
C55-phosphate dissolved in NaHCO3 (50 mM) : DMSO (1 : 4) (4 mM, 2.81 μL) were placed 
in a 1.5 mL Eppendorf tube. To a stirred reaction mixture, P60 (1 mg/μL, 30 μL) was added 
(total volume of reaction mixture: 60 μL adjust with Tris buffer (50 mM, pH = 8.0)). The 
reaction mixture was incubated for 1 h at 37 oC. To a reaction mixture, tunicamycin (10 
mg/mL stock solution, 0.25 μL) was added, then inhibitor molecule (0 - 100 g/mL in Tris 
buffer) and UDP-GlcNAc (10 mM stock solution, 1.88 μL) were added. The reaction 
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mixture was incubated for 1 h at 37 oC, and quenched with water saturated n-butanol 
(150μL). Two phases were mixed via vortex for 2 min and centrifuged at 25,000 xg for 10 
min. The upper n-butanol phase was assayed via reverse-phase HPLC. The n-butanol phase 
(30 μL) was injected into HPLC (solvent: a gradient elution of CH3OH/0.05 M aq. 
NH4HCO3 = 70 : 30 to 100 : 0 over 30 min; UV: 350 nm; flow rate: 1.0 mL/min; column: 
Luna 5μm C8, 100 A, 250 x 4.60 mm), and the area of the peak for C55-lipid II-N
ε-C6-
dansyl-FITC was quantified to obtain the IC50 value. The IC50 values were calculated from 
plots of the percentage product inhibition versus the inhibitor concentration. All inhibition 
curves, Michaelis-Menten plots and Lineveaver-Burk plots were obtained by using 
GraphPad Prism 7.04. 
 
UV/VIS spectroscopy-based assay 
Park’s nucleotide-Nε-C6-dansylthiourea (1e) (2 mM stock solution, 1.88 μL), CHAPS (20%, 
1.25 μL), -mercaptoethanol (50 mM, 5 μL), MgCl2 (0.5 M, 5 μL), KCl (2 M, 5 μL), and 
C55-phosphate dissolved in NaHCO3 (50 mM) : DMSO (1 : 4) (4 mM, 2.81 μL) were placed 
in a 1.5 mL Eppendorf tube. To a stirred reaction mixture, HyMraY (4.18 mg/mL, 1 μL) 
was added (total volume of reaction mixture: 50 μL adjust with Tris buffer (50 mM, pH = 
8.0)). The reaction mixture was incubated for 1 h at 37 oC. To a reaction mixture, inhibitor 
molecule (0 - 100 g/mL in Tris buffer), UDP-GlcN-C6-FITC (10 mM stock solution, 1.88 
μL), and P60 (1 mg/μL, 30 μL) or HyMurG (5.2 mg/mL, 5 μL) were added. The reaction 
mixture was incubated for 1 h at 37 oC, and quenched with water saturated n-butanol 
(150μL). Two phases were mixed via vortex for 2 min and centrifuged at 25,000 xg for 10 
min. The upper n-butanol phase was washed with n-butanol saturated 1 : 1 mixture of 
saline/0.2 M mannitol (50 μL, thrice) and then, the washed n-butanol phase (20 μL) was 
transferred to a 384 well black plate and fluorescence was measured at an excitation of 485 
nm and emission of 528 nm. The IC50 values were calculated from plots of the percentage 
product inhibition versus the inhibitor concentration. All inhibition curves, Michaelis-
Menten plots and Lineveaver-Burk plots were obtained by using GraphPad Prism 7.04. 
 
 
Figure S2. Michaelis-Menten plots and Lineweaver-Burk plots for 2e-C55 at the 
different concentrations of UDP-GlcNAc. 
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Figure S3. Superimposed Lineweaver-Burk plots for 2e-C55 at the different 
concentrations of UDP-GlcNAc. 
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Figure S4. Michaelis-Menten plots and Lineweaver-Burk plots for UDP-GlcNAc at 
the different concentrations of 2e-C55. 
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Figure S5. Superimposed Lineweaver-Burk plots for UDP-GlcNAc at the different 
concentrations of 2e-C55 (93.8-350 M) 
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Figure S6. Inhibition curve for 2e-C55 by restocetin A against MurG. 
 
 
 
 
Figure S7. Inhibition curve for 1e by restocetin A against MraY (IC50 0.81 M against 
MsmegMraY). 
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Figure S8. MsmegMraY kinetics in the presence of ristocetin A at different 
concentrations of 1e. 
 
 
 
 
Figure S9. MsmegMraY kinetics in the presence of ristocetin A at different 
concentrations of C55-P. 
 
 
 
 
Figure S10. Product-time curve for the MurG-catalyzed reactions (2e-C55 (75 
UDP-GlcNAc (375 . 
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Figure S11. Effect of DMSO on the MurG activity. 
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Table S1. MraY, WecA and AglH assays [7], [8] against 15 and 16. 
  
 
Each experiment was performed two-three times. Analyses: HPLC-based method 
 
 
 
Determination of cytotoxicity in Vero Cells 
Selected molecules were tested for cytotoxicity (IC50) in Vero cells via MTT colorimetric 
assay. Vero cell line was cultured in Complete eagle`s minimum essential growth medium 
(EMEM) containing L-glutamine, sodium pyruvate, minimum essential amino acids, 
penicillin-streptomycin and 10% fetal bovine serum. Inoculating number of cells were 
400,000 cells/mL and a final 40,000 cells/well. After 48h of exposure of molecules to this 
cell line at concentrations ranging from 0.78 to 100 g/mL, 10 L of MTT, yellow 
tetrazolium dye; was added to each well and the assay was terminated by removing the 
media and addition of 100 L of DMSO. The Viability was assessed on the basis of cellular 
conversion of MTT into a purple formazan product. The absorbance of the colored 
formazan product was measured at 570 nm by BioTek Synergy HT Spectrophotometer. 
Linearity of the MTT response to the cell number was determined.  
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Figure S12. MTT assay in Vero cells. 
 
 
 
 
Structural comparison between MurG proteins. 
Hydrogenivirga sp. (128-5-R1-1) and M. tuberculosis (H37Rv): 26% identity /42% 
similarity 
 
 
 
 
S24 
 
E. coli (K-12) and M. tuberculosis (H37Rv): 39% identity /53% similarity 
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